IGF1 ELISA Kit (Insulin-Like Growth Factor 1)

Details for Product IGF1 ELISA Kit No. ABIN612712, Supplier: Log in to see
  • IGF-I
  • IGF1A
  • IGFI
  • C730016P09Rik
  • Igf-1
  • Igf-I
  • Npt2B
  • IGF-1
  • IGF-IB
  • igf1
  • IGF-1L
  • IGF-1a
  • IGF1
  • insulin-like growth factor 1 (somatomedin C)
  • insulin-like growth factor 1
  • insulin-like growth factor I
  • prepro IGF-I
  • IGF1
  • Igf1
  • LOC100136741
  • igf1
  • IGF-I
Cow (Bovine) IGF1 ELISA Kit
Kits with alternative reactivity to:
Method Type
Sandwich ELISA
Minimum Detection Limit
0.8 ng/mL
Log in to see
Supplier Product No.
Log in to see
Purpose The AssayMax Human IGF-1 ELISA kit is designed for detection of human IGF-1 in plasma, serum and cell culture supernatants
Brand AssayMax
Sample Type Plasma, Cell Culture Supernatant
Analytical Method Quantitative
Detection Method Colorimetric
Components Human IGF-1 Microplate: A 96 well polystyrene microplate (12 strips of 8 wells) coated with a monoclonal antibody against human IGF-1. Sealing Tapes: Each kit contains 3 pre-cut, pressure-sensitive sealing tapes, which can be cut to fit the format of the individual assay. Human IGF-1 Standard: Human IGF-1 in a buffered protein base (72 ng, lyophilized). 1 Biotinylated IGF-1 Antibody (50x): A 50-fold concentrated biotinylated polyclonal antibody against IGF-1 (160µl). Streptavidin-Peroxidase Conjugate (SP Conjugate): A 100-fold concentrate (80µl). MIx Diluent Concentrate (10x): A 10-fold concentrated buffered protein base (30 ml). Plasma/Serum Pretreatment Buffer (1x): A ready to use plasma/serum pretreatment buffer (15 ml). Wash Buffer Concentrate (20x): A 20-fold concentrated buffered surfactant (30 ml). Chromogen Substrate: A ready-to-use stabilized peroxidase chromogen substrate tetramethylbenzidine (8 ml). Stop Solution: A 0.5 N hydrochloric acid to stop the chromogen substrate reaction (12 ml).
Material not included Microplate reader capable of measuring absorbance at 450 nm. Pipettes (1-20 µL, 20-200 µL, 200-1000µLand multiple channel). Deionized or distilled reagent grade water.
Alternative Name Insulin-like Growth Factor 1 (IGF-1) (IGF1 ELISA Kit Abstract)
Background Insulin-like growth factor 1 (IGF-1) is a 70 amino acid polypeptide protein hormone with molecular mass of 7.65 kDa. IGF-1 is produced primarily by the liver in response to the stimulation of growth hormone. It is transported in plasma bound to different forms of IGF-1 binding proteins. It also binds to specific IGF-1 tyrosine kinase receptor and the insulin receptor. Inhibition IFG-1 receptor reduces pancreatic cancer growth and angiogenesis. IGF-I regulates cellular proliferation, differentiation, apoptosis, and amyloid precursor protein family (4 - 5). It may be important in the pathophysiological processes underlying chronic disease, including type 2 diabetes mellitus, coronary heart disease, cancer and Alzheimer's disease (6 - 8). Increased levels of IGF lead to an increased risk of cancer. IGF-I stimulates osteoblast proliferation, bone formation, and increases bone volume. It is a potent neurotrophic as well as a neuroprotective factor found in the central and the peripheral nervous systems of the brain.
Pathways RTK Signaling, Intracellular Steroid Hormone Receptor Signaling Pathway, Peptide Hormone Metabolism, Hormone Activity, Regulation of Intracellular Steroid Hormone Receptor Signaling, Regulation of Hormone Metabolic Process, Regulation of Hormone Biosynthetic Process, Stem Cell Maintenance, Glycosaminoglycan Metabolic Process, Regulation of Carbohydrate Metabolic Process, Autophagy, Smooth Muscle Cell Migration, Activated T Cell Proliferation, Positive Regulation of fat Cell Differentiation
Sample Volume 50 μL
Assay Time < 5 h
Plate Pre-coated
Protocol This assay employs a quantitative sandwich enzyme immunoassay technique, which measures IGF-1 in less than5 hours. A monoclonal antibody specific for human IGF-1 has been pre-coated onto a microplate. Human IGF-1 in standards and samples is sandwiched by the immobilized antibody and biotinylated polyclonal antibody specific for human IGF-1, which is recognized by a streptavidin-peroxidase conjugate. All unbound material is then washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.
Reagent Preparation

Freshly dilute all reagents and bring all reagents to room temperature before use. If crystals have formed in the concentrate, mix gently until the crystals have completely dissolved. MIx Diluent Concentrate (10x): Dilute the MIx Diluent Concentrate 1:10 with reagent grade water. Store for up to 1 month at 2-8°C. 2 IGF-1 Standard: Reconstitute the 72 ng of human IGF-1 Standard with 3 ml of MIx Diluent to generate a stock solution of 24 ng/ml. Allow the standard to sit for 10 minutes with gentle agitation prior to making dilutions. Prepare duplicate or triplicate standard points by serially diluting the Standard solution (24 ng/ml) 1:2 with equal volume of MIx Diluent to produce 12, 6, 3, 1.5 and 0.75 ng/ml. MIx Diluent serves as the zero standard (0 ng/ml). Any remaining solution should be frozen -20°C. at Standard Point Dilution [hIGF-1] (ng/ml) P1 1 part Standard (24 ng/ml) 24.00 P2 1 part P1 + 1 part MIx Diluent 12.00 P3 1 part P2 + 1 part MIx Diluent 6.00 P4 1 part P3 + 1 part MIx Diluent 3.00 P5 1 part P4 + 1 part MIx Diluent 1.50 P6 1 part P5 + 1 part MIx Diluent 0.75 P7 MIx Diluent 0.00 Biotinylated IGF-1 Antibody (50x): Spin down the antibody briefly and dilute the desired amount of the antibody 1:50 with MIx Diluent. Any remaining solution should be frozen at -20°C. Wash Buffer Concentrate (20x): Dilute the Wash Buffer Concentrate 1: 20 with reagent grade water. Streptavidin-Peroxidase Conjugate (100x): Spin down the SP Conjugate briefly and dilute the desired amount of the conjugate 1:100 with MIx Diluent. Any remaining solution should be frozen at -20°C.

Sample Collection Plasma: Collect plasma using one-tenth volume of 0.1 M sodium citrate as an anticoagulant. Centrifuge samples at 2000 x g for 10 minutes and assay. Pretreatment plasma sample as follows: Add 20 µl of plasma sample into 60 µl of Plasma/Serum pretreatment buffer and incubate for 10 minutes at room temperature. Dilute pretreated samples 1:10 into MIx Diluent and assay. The final dilution factor is 40. Store samples at -20°C or below for up to 3 months. Avoid repeated freeze- thaw cycles. (EDTA or Heparin can also be used as anticoagulant.) Serum: Samples should be collected into a serum separator tube. After clot formation, centrifuge samples at 2000 x g for 10 minutes. Remove serum and assay. Pretreatment plasma sample as follows: Add 20 µl of serum sample into 60 µl of Plasma/Serum pretreatment buffer and incubate for 10 minutes at room temperature. Dilute pretreated samples 1:10 into MIx Diluent (1x) and assay. The final dilution factor is 40x. Store serum at -20°C or below. Avoid repeated freeze-thaw cycles. Cell Culture Supernatants: Centrifuge cell culture media at 2000 x g for 10 minutes to remove debris. Collect supernatants and assay. Store samples at -20°C or below. Avoid repeated freeze- thaw cycles.
Assay Procedure

Prepare all reagents, working standards and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20 - 30 °C). Remove excess microplate strips from the plate frame and return them immediately to the foil pouch with desiccant inside. Reseal the pouch securely to minimize exposure to water vapor and store in a vacuum desiccator. Add 50 µL of Standard or sample per well, and cover wells and incubate for two hours. Start the timer after the last sample addition. Wash five times with 200 µL of Wash Buffer manually. Invert the plate each time and decant the contents, hit it 4-5 times on absorbent paper towel to completely remove the liquid. Add 50 µL of Biotinylated IGF-1 Antibody to each well and incubate for two hours. Wash a microplate as described above. Add 50 µL of Streptavidin-Peroxidase Conjugate per well and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance. Wash a microplate as described above. Add 50 µL of Chromogen Substrate per well and incubate for about 10 minutes or till the optimal blue color density develops. Gently tap plate to ensure thorough mixing and break the bubbles in the well with pipette tip. Add 50 µL of Stop Solution to each well. The color will change from blue to yellow. Read the absorbance on a microplate reader at a wavelength of 450 nm immediately. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections. Otherwise, read the plate at 450 nm only. Please note that some unstable black 3 particles may be generated at high concentration points after stopping the reaction for about 10 minutes, which will reduce the readings.

Calculation of Results

Calculate the mean value of the triplicate readings for each standard and sample. To generate a Standard Curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm absorbance on the y-axis. The best-fit line can be determined by regression analysis using log-log or four-parameter logistic curve-fit. Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor. Standard Curve The curve is provided for illustration only. A standard curve should be generated each time the assay is performed.

Assay Precision Intra-assay and inter-assay coefficients of variation were 4.9 % and 7.1% respectively.
Restrictions For Research Use only
Handling Advice The kit should not be used beyond the expiration date.
Storage 4 °C/-20 °C
Storage Comment Store kit at 2-8°C or -20°C upon arrival up to the expiration date. Opened MIx Diluent may be stored for up to 1 month at 2-8°C. Store reconstituted reagents at <-20°C. Opened unused strip wells may return to the foil pouch with the desiccant pack, reseal along zip-seal. May be stored for up to 1 month in a vacuum desiccator.
Supplier Images
ELISA image for Insulin-Like Growth Factor 1 (IGF1) ELISA Kit (ABIN612712) Insulin-Like Growth Factor 1 (IGF1) ELISA Kit
Product cited in: Serafín, Agüí, Yáñez-Sedeño, Pingarrón: "Electrochemical immunosensor for the determination of insulin-like growth factor-1 using electrodes modified with carbon nanotubes-poly(pyrrole propionic acid) hybrids." in: Biosensors & bioelectronics, Vol. 52, pp. 98-104, 2013 (PubMed).

Karabulut, Duranyıldız, Tas, Gezer, Akyüz, Serilmez, Ozgür, Yasasever, Vatansever, Aykan: "Clinical significance of serum circulating insulin-like growth factor-1 (IGF-1) mRNA in hepatocellular carcinoma." in: Tumour biology, 2013 (PubMed).

Background publications Moser, Schachtschneider, Lang, Gaumann, Mori, Zimmermann, Schlitt, Geissler, Stoeltzing: "Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis." in: European journal of cancer (Oxford, England : 1990), Vol. 44, Issue 11, pp. 1577-86, 2008 (PubMed).

Adlerz, Holback, Multhaup, Iverfeldt: "IGF-1-induced processing of the amyloid precursor protein family is mediated by different signaling pathways." in: The Journal of biological chemistry, Vol. 282, Issue 14, pp. 10203-9, 2007 (PubMed).

Sima, Li: "Diabetes and Alzheimer's disease - is there a connection?" in: The review of diabetic studies : RDS, Vol. 3, Issue 4, pp. 161-8, 2007 (PubMed).

Butovsky, Koronyo-Hamaoui, Kunis, Ophir, Landa, Cohen, Schwartz: "Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, Issue 31, pp. 11784-9, 2006 (PubMed).

Sandhu: "Insulin-like growth factor-I and risk of type 2 diabetes and coronary heart disease: molecular epidemiology." in: Endocrine development, Vol. 9, pp. 44-54, 2005 (PubMed).

Remacle-Bonnet, Garrouste, Heller, André, Marvaldi, Pommier: "Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways." in: Cancer research, Vol. 60, Issue 7, pp. 2007-17, 2000 (PubMed).

Jones, Clemmons: "Insulin-like growth factors and their binding proteins: biological actions." in: Endocrine reviews, Vol. 16, Issue 1, pp. 3-34, 1995 (PubMed).

Sandberg-Nordqvist, Ståhlbom, Reinecke, Collins, von Holst, Sara: "Characterization of insulin-like growth factor 1 in human primary brain tumors." in: Cancer research, Vol. 53, Issue 11, pp. 2475-8, 1993 (PubMed).

Did you look for something else?